• About ARCA
  • Our Science
  • Clinical Trials
  • Collaborations
  • Investors
  • Contact Us

ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

Posted on December 15, 2020 by ARCA IT - Press Release, Uncategorized

12.15-rNAPc2-FPE-ASPEN-COVID-Trial

ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders

Posted on December 9, 2020 by ARCA IT - Press Release, Uncategorized

12.9-ARCA-Annual-Meeting-Location-Change-FINAL

AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

Posted on November 23, 2020 by ARCA IT - Press Release, Uncategorized

11.23-AB201-COVID-FDA-Fast-Track-Designation

ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Posted on November 2, 2020 by ARCA IT - Press Release, Uncategorized

11.2-3Q20-Financial-Results-and-Business-Update

ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

Posted on October 7, 2020 by ARCA IT - Press Release, Uncategorized

10.07-AB201-COVID-IND-Approval-Study-May-Proceed-FINAL

ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality

Posted on October 5, 2020 by ARCA IT - Press Release, Uncategorized

10.5-Management-Promotions

ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

Posted on September 21, 2020 by ARCA IT - Press Release, Uncategorized

9.21-AB201-COVID-IND-Submission

ARCA BIOPHARMA ANNOUNCES COMPLETION OF FDA PRE-IND CONSULTATION UNDER CORONAVIRUS TREATMENT ACCELERATION PROGRAM FOR AB201 AS A POTENTIAL TREATMENT FOR SEVERE COVID-19

Posted on August 12, 2020 by ARCA IT - Press Release, Uncategorized

AB201-COVID-Pre-IND-Completed

ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Posted on August 5, 2020 by ARCA IT - Press Release, Uncategorized

ARCA-2Q20-Financial-Results-and-Business-Update

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Posted on July 7, 2020 by ARCA IT - Press Release, Uncategorized

ARCA-UC-COVID-19-CV-Paper-Published-JACC-JBTS

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
  • Last

Recent Posts

  • ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
  • ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
  • AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
  • ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
  • ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

Archives

  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • February 2020
  • November 2019
  • September 2019
  • August 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • September 2018
  • August 2018
  • July 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • November 2017
  • September 2017
  • August 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • November 2016
  • October 2016
  • August 2016
  • May 2016
  • April 2016
  • March 2016
  • January 2016
  • November 2015
  • September 2015
  • August 2015
  • June 2015

Categories

  • Press Release
  • Uncategorized
ARCA Biopharma Logo
  • 720-940-2100
  • 10170 Church Ranch Way, Suite 100
  • Westminster, CO 80021
  • About ARCA
  • Our Science
Slash
  • Clinical Trials
  • Collaborations
Slash
  • Investors
  • Contact
    • © 2021 ARCA Biopharma.

    • Slash
      • Sitemap
      • Legal Disclaimer
Designed by Watermark